仑伐替尼甲酸盐 T8541

Product Introduction
Bioactivity


英文名: Lenvatinib mesylate

描述: Lenvatinib mesylate (E7080 (mesylate)) 是一种口服具有活力的，多靶点酪氨酸激酶抑制剂，能够抑制血管内皮生长因子受体(VEGFR1-3)，成纤维细胞生长因子受体(FGFR1-4)，干细胞因子受体(KIT)，血小板衍生生长因子受体(PDGFR)，转染期间重排(RET)，具有效抗癌作用。

体外活性: Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor α (PDGFRα), stem cell factor receptor (KIT), and rearranged during transfection (RET).?These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors[1].

存储条件: store under nitrogenPowder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 16.67 mg/mL (31.87 mM)


关键字: PDGFR | Inhibitor | Lenvatinib mesylate | E-7080 | inhibit | VEGFR | c-Kit | RET | Vascular endothelial growth factor receptor | Fibroblast growth factor receptor | CD117 | SCFR | Lenvatinib Mesylate | FGFR | E7080 | E 7080 | Platelet-derived growth factor receptor | Lenvatinib

相关产品: (Z)-FeCP-oxindole | CP-547632 TFA | RAF265 | NVP-BAW2881 | GW297361 | MGCD-265 analog | ODM-203 | LY2874455 | Penduletin | Ponatinib

相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library | EMA Approved Drug Library

仑伐替尼甲酸盐 T8541信息由TargetMol中国为您提供，如您想了解更多关于仑伐替尼甲酸盐 T8541报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途